Previous studies indicated that like E2F1, E2F2 exhibited oncogenic or tumor suppressive activity, and overexpression of E2F2 contributed to the development of several solid tumors, indicating worse patient outcome (36, 37). This evidence concerns the gene E2F1 and neoplasm.